Treatment-resistant depression is one of the most significant clinical challenges in psychiatric practice. The primary aim of the present study was to assess the efficacy and tolerability of intranasal esketamine on depressive symptoms in a real-world outpatient setting. A secondary objective was to explore the potential benefits of intranasal esketamine on hopelessness and suicide risk...
Recent evidence suggests that the rapid-acting antidepressant ketamine has immune regulatory functions. The complement system is an important component of the innate immune response and plays a key role in synaptic plasticity. An increase in complement component 3 (C3) expression was previously found in the prefrontal cortex of individuals with depression. Given the complement system's role in...
Treatment-resistant depression (TRD) presents substantial clinical challenges, particularly in patients with Alzheimer's disease (AD) and older adults experiencing late-life depression. Traditional monoaminergic therapies often fail in this population due to neurodegenerative changes that impact receptor dynamics and neurotransmitter systems. Emerging evidence suggests that N-methyl-D-aspartate...
Treatment-resistant depression (TRD) is associated with reduced quality of life and elevated mortality, posing a major challenge to psychiatric care. After non-response to conventional treatments, next-level interventions such as (es)ketamine are recommended, though remission rates remain variable. Identifying reliable markers of treatment response is therefore critical. Recent evidence...
Treatment-resistant depression (TRD) remains a challenge, but intravenous racemic ketamine offers rapid antidepressant effects. Reliable biomarkers are needed. In this study, we examined kynurenine pathway metabolites and inflammatory cytokines as predictors of ketamine response. The Bio-K study was a multicenter, open-label trial of 74 patients with TRD who received 3 ketamine infusions over...
Consistent dream sequences that appear genuine and become more upsetting as they progress are known as nightmares. A prevalent condition that significantly impairs psychosocial performance and lowers quality of life is major depression. Insomnia and nightmares independently but additionally have an impact on the exacerbation of depression. Objectives: To find the correlation between depression...
Depressive disorder is one of the most prevalent mental health problems with a significant impact on quality of life. In Indonesia, the 2018 National Health Survey (Riskesdas) reported a prevalence of depression among adolescents at 6.2%, with risk increasing along with age. The high relapse rate makes depression a chronic condition that requires long-term intervention strategies....
Ketamine's potential as a rapid-acting antidepressant was first identified in 2000, despite its long-standing use as an anesthetic agent. Clinically, ketamine alleviates depressive symptoms, including the difficult to treat symptom of anhedonia, within hours, with the effects of a single dose lasting for days. Since then, research has focused on uncovering the mechanisms underlying its rapid...
While traditional mindfulness-based interventions demonstrate effectiveness in improving mental health outcomes, their delivery methods face significant challenges related to accessibility and engagement. Geographic barriers to trained facilitators, time constraints for in-person sessions, and participant dropout rates of 15% to 30% due to perceived monotony limit intervention reach and...
Background and Objectives: Adolescence is a critical yet vulnerable developmental stage, characterized by increased exposure to stressful life events (SLEs), which are strongly linked to the onset and progression of depression. Although mindfulness has been consistently associated with lower depressive symptoms, the mechanisms underlying this relationship-particularly in adolescents-remain...